FIELD: biotechnology.
SUBSTANCE: disclosed are antibodies specific to the catalytic domain of FokI nuclease, and methods for production thereof. Also disclosed are conjugates of said antibodies with a detectable label. Invention also relates to the use of antibodies and conjugates for determining the presence of a catalytic domain of FokI nuclease in a sample.
EFFECT: invention can be used to assess safety and efficacy of various types of therapy involving gene editing.
28 cl, 1 dwg, 7 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LIBRARIES OF SYNTHETIC POLYPEPTIDES AND METHODS OF OBTAINING VERSIONS OF POLYPEPTIDES WITH NATURAL DIVERSITY | 2010 |
|
RU2562163C2 |
| NECTIN-4 BINDING PROTEINS AND METHODS OF THEIR APPLICATION | 2018 |
|
RU2805252C2 |
| ANTI-CXCR4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | 2014 |
|
RU2675516C2 |
| ANTIBODIES FOR SPECIFIC BINDING OF STAPHYLOCOCCUS AUREUS ALPHA-TOXIN AND METHODS OF APPLICATION | 2012 |
|
RU2620065C2 |
| COMPOSITIONS AND METHODS FOR SUPPRESSION OF CANCER STEM CELLS | 2016 |
|
RU2752610C1 |
| ANTI-C5 ANTIBODIES AND THEIR USE | 2018 |
|
RU2774716C2 |
| CANCER TREATMENT WITH CHIMERIC CD33 ANTIGEN RECEPTOR | 2015 |
|
RU2747384C2 |
| LOX1-SPECIFIC BINDING PROTEINS AND THEIR APPLICATION METHODS | 2015 |
|
RU2764993C2 |
| ANTIBODIES TO CHIMERIC ANTIGEN RECEPTORS DERIVED FROM 4G7 | 2020 |
|
RU2826051C2 |
| MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN-31 | 2012 |
|
RU2588462C2 |
